| Nov 19 |
Akari Therapeutics Regains Full Nasdaq Compliance
|
| Nov 15 |
This Akari Therapeutics Insider Increased Their Holding By 69% Last Year
|
| Nov 14 |
Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio
|
| Nov 8 |
Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger
|
| Oct 15 |
Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger
|
| Sep 17 |
Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics
|
| Aug 19 |
Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights
|
| Aug 19 |
Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy
|
| Jun 5 |
Akari Therapeutics announces interm CEO employment contract
|
| Jun 5 |
Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders
|
